AG&M annual report 2018
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
AG&M Science Impressions <strong>2018</strong><br />
Marc Besselink and Marin Strijker<br />
pancreatic resection are collected. The biobank started<br />
in 2015 and is incorporated in the Parelsnoer Institute,<br />
which is a nationwide network established by the Dutch<br />
Federation of University Medical Centers (NFU). The<br />
Parelsnoer Institute aims to facilitate central data and<br />
IT infrastructure in the UMC’s, striving for uniform data<br />
and biomaterial collection.<br />
All patients undergoing pancreatic resection are<br />
included. After providing informed consent, data and<br />
biomaterials are collected. In the preoperative setting<br />
DNA, plasma (10 mL tube) and serum (10 mL tube) are<br />
collected. Directly after resection, biopsies (2x tumor<br />
tissue, 1x normal pancreatic tissue, 1x normal spleen/<br />
duodenum) from the resected specimen are obtained;<br />
samples are fresh-frozen and stored at -80ºC. In the<br />
postoperative phase serum and plasma are collected at<br />
several moments during follow-up. This far, more than<br />
1300 patients have been included in 12 centers; all 8<br />
UMC’s, but also several teaching hospitals participate.<br />
Research proposals for the use of samples are<br />
evaluated by the DPCG scientific committee.<br />
ADAM12 as a stroma marker in<br />
pancreatic cancer<br />
Recently, the first analyses of samples from the Dutch<br />
Pancreas Biobank have been performed. This study,<br />
supervised by dr. Maarten Bijlsma, evaluates the<br />
serum marker A Disintegrin And Metalloprotease 12<br />
(ADAM12). Earlier research has shown that in patients<br />
with pancreatic cancer ADAM12 is upregulated<br />
specifically in the stroma of tumor tissue compared<br />
to normal pancreatic tissue. Moreover, in a cohort<br />
of 60 patients who underwent resection because of<br />
pancreatic cancer, high serum ADAM12 was associated<br />
with poor prognosis. In patients with metastatic disease<br />
treated with nab-paclitaxel and gemcitabine (n=184),<br />
low ADAM12 levels predicted response to treatment.<br />
The value of ADAM12 as a non-invasive biomarker<br />
in resected pancreatic cancer will be validated using<br />
samples from the Dutch Pancreas Biobank (n=164); the<br />
results are currently being analyzed.<br />
23